article thumbnail

FDA clears AstraZeneca, Merck drug to treat some genetic breast cancers early

Bio Pharma Dive

Lynparza is the first drug targeting BRCA mutations to be approved for use in early breast cancer, a decision that could lead to more genetic testing.

Genetics 321
article thumbnail

A new startup gets Takeda's backing to take complex genetic medicines 'off the shelf'

Bio Pharma Dive

Ensoma Therapeutics debuts with a lucrative alliance with the Japanese pharma and an unusual way to deliver genetic medicines into the body.

Genetics 328
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Merck pays Seattle Genetics $1.7B as antibody cancer drugs continue comeback

Bio Pharma Dive

Merck's deal for Seattle Genetics' antibody-drug conjugate comes as Gilead agreed to acquire rival developer Immunomedics in the biotech industry's largest buyout of 2020.

Genetics 312
article thumbnail

BridgeBio secures $1.25bn for genetic therapy development

Pharmaceutical Technology

BridgeBio Pharma has secured strategic financing of $1.25bn from Blue Owl Capital and CPP Investments for genetic therapies.

Genetics 246
article thumbnail

Lilly and ProQR to expand genetic medicine development agreement

Pharmaceutical Technology

Eli Lilly and Company has expanded a licencing and partnership agreement with ProQR Therapeutics to discover, develop and market new genetic medicines. The post Lilly and ProQR to expand genetic medicine development agreement appeared first on Pharmaceutical Technology.

Genetics 328
article thumbnail

Scribe and Sanofi expand genetic therapy development deal

Pharmaceutical Technology

Scribe Therapeutics and Sanofi have expanded partnership to progress the development of in vivo genetic therapies to treat genomic diseases.

Genetics 246
article thumbnail

Pelican and Primordial Genetics merge to form biotech company Primrose Bio

Pharmaceutical Technology

Pelican Technology has combined business with Primordial Genetics under a deal to create a private biotechnology company Primrose Bio.

Genetics 263